Yves Sabbagh, Phd Email and Phone Number
Yves Sabbagh, Phd work email
- Valid
- Valid
- Valid
- Valid
Yves Sabbagh, Phd personal email
Yves Sabbagh, Phd phone numbers
• Discovery scientist responsible for the identification and evaluation of novel therapeutic approaches for rare genetic disorders • Maintained collaborative network among outside thought leaders and outstanding scientists in renal, bone, and mineral metabolism area through 18 years of experience in the field of genetic bone diseases and in the regulation of mineral ion homeostasis• Excellent analytic, communication and presentation skills with 14 years of managing scientists and research associates
-
Chief Scientific OfficerInozyme Pharma Oct 2020 - PresentBoston, Massachusetts, Us
-
Head Of Rare Renal And Musculoskeletal Diseases ResearchSanofi Genzyme Jan 2020 - Oct 2020Paris, France, Fr -
R&D DirectorSanofi Genzyme Apr 2017 - Jan 2020Paris, France, Fr• Perform diligence on external opportunities working closely with business development, external innovation and commercial group.• Assist in driving strategy for bone indications as part of the Rare Renal and Bone cluster.• Established sponsored researched agreement on several rare bone diseases with different academic partners.• Review and perform due diligence on external opportunities for new indications and new platforms• Project leader advancing efforts in a genetic rare bone disease. Identified lead molecules and performed proof of concept studies in pre-clinical disease model demonstrating efficacy.
-
Senior Principal Scientist/Associate DirectorSanofi Genzyme Apr 2015 - Mar 2017Paris, France, Fr• Project leader advancing efforts in a genetic rare bone disease. Identified lead molecules and performed proof of concept studies in pre-clinical disease model demonstrating efficacy.• Identified novel biomarkers in the pre-clinical disease model using serum proteomic approach working with the translational medicine group to validate biomarkers in human patient samples.• Establish external collaborations for new indications
-
Principal Scientist/Associate DirectorGenzyme, A Sanofi Company Mar 2013 - Mar 2015• Project leader directing efforts in genetic rare bone diseases. Evaluating several strategies for a specific target in both in vitro and in vivo pre-clinical disease models.• Directed scientific activities of ~40 FTEs across multiple functional groups (proteomics, biologics, translational sciences, histology and pathology, pharmacology).• Validated a pre-clinical mouse model with a collaborator for rare genetic lung disease, pulmonary alveolar microlithiasis, (PAM). Identified biomarkers and novel strategies for the treatment of PAM a disease with an unmet medical need with no current treatment.
-
Senior ScientistGenzyme, A Sanofi Company Apr 2010 - Mar 2013• Initiated efforts in genetic rare bone diseases. Evaluating several strategies for a specific target in both in vitro and in vivo pre-clinical disease models.• Transitioned project evaluating novel therapeutic targets for osteogenesis imperfecta (OI). Setup collaborations to obtain clinical samples from OI patients for target validation.• Evaluated novel therapeutic approaches to improve bone health, ameliorate cardiovascular damage and normalize endocrine imbalance associated with chronic kidney disease.• Identified therapeutic targets through pathway analysis in osteocytes during chronic kidney disease in the jck mouse a model and clinical bone biopsies of CKD-MBD. • Collaborated with several academic groups (Drs Moysés, Brazil and Massy, France) in identifying the mechanism of action driving the pleiotropic effects of Sevelamer on bone and the cardiovascular system.• Proposed strategy to identify the mechanisms driving vascular calcification in chronic kidney disease. Evaluated small molecule inhibitor of BMPRII in a uremic model prone to vascular calcification. Performed translational studies involving anti-TGF- therapy (1D11) and evaluated effects on left ventricular hypertrophy and aortic calcification.• Validated Npt2b as a therapeutic target for phosphate control in 2 uremic models. Demonstrated better phosphate control of Sevelamer in Npt2b KO mouse.• Directed PK/PD studies of Hectorol vs. Calcitriol in different models and determined their differential effects on FGF23 levels.
-
Staff Ii ScientistGenzyme Corporation Nov 2005 - Mar 2010• Initiated studies involved in the identification of novel intestinal targets for phosphate management by microarray analysis using the Npt2b knockout mouse.• Established electrocautery/nephrectomy mouse model in-house.• Characterized the Npt2b conditional knockout mouse to validate Npt2b as a therapeutic target for phosphate control.• Collaborated with Dr Ferraris’ lab at UMDNJ looking at the effects of fructose on Vitamin D metabolism.• Evaluated the mechanism of actions of TSH in ovariectomized rats in both prevention and restoration models by characterizing effects on osteoprogenitor cells as a new anabolic agent for the treatment of osteoporosis.
-
Instructor In MedicineMassachusetts General Hospital/ Harvard Medical School Sep 2005 - Nov 2005Boston, Ma, Us• Initiated studies aimed at identifying the novel phosphate transporters involved in the terminal differentiation of hypertrophic chondrocytes. These laid the foundation resulting in new publications in the group.• Characterized alternate sodium-phosphate co-transporters in the Npt2a knockout mouse to assess their importance in the maintenance of phosphate homeostasis. -
Post-Doctoral FelllowHarvard Medical School 2002 - 2005• Demonstrated using different genetic (VDR -/- and Hyp mice) and diet-induced hypophosphatemic mice and derived primary cell culture, that expansion of the hypertrophic chondrocyte layer in the growth plate is due to phosphate controlled impairment in the mitochondrial apoptotic pathway.• Collaborated with Dr. Kenneth White (Indiana University) and showed that phosphate and vitamin D independently regulate FGF23 in the vitamin D receptor (VDR) knockout mouse.• Collaborated with Dr. Phillip Hinds (Tufts University) and demonstrated impaired bone development and increased mesenchymal progenitor cells in calvaria of RB1-/- mice.• Characterized the role of vitamin D receptor ablation on osteogenesis in primary osteoblast cultures derived from VDR null mice.
-
Phd StudentMontreal Children'S Hospital 1998 - 2002
Yves Sabbagh, Phd Skills
Yves Sabbagh, Phd Education Details
-
Mcgill UniversityBiology -
Université LavalMicrobiology And Immunology
-
Mcgill UniversityBiochemistry
Frequently Asked Questions about Yves Sabbagh, Phd
What company does Yves Sabbagh, Phd work for?
Yves Sabbagh, Phd works for Inozyme Pharma
What is Yves Sabbagh, Phd's role at the current company?
Yves Sabbagh, Phd's current role is Chief Scientific Officer at Inozyme Pharma.
What is Yves Sabbagh, Phd's email address?
Yves Sabbagh, Phd's email address is yv****@****yme.com
What is Yves Sabbagh, Phd's direct phone number?
Yves Sabbagh, Phd's direct phone number is (508)-872*****
What schools did Yves Sabbagh, Phd attend?
Yves Sabbagh, Phd attended Mcgill University, Université Laval, Mcgill University.
What are some of Yves Sabbagh, Phd's interests?
Yves Sabbagh, Phd has interest in Science And Technology, Education.
What skills is Yves Sabbagh, Phd known for?
Yves Sabbagh, Phd has skills like Molecular Biology, Life Sciences, Cell Culture, In Vitro, In Vivo, Biotechnology, Assay Development, Drug Discovery, Elisa, Cell Biology, Biochemistry, Lifesciences.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial